title: Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
abstract: We developed a local AIT using PEL cultured with TCGF combined with preadministration of OK-432. Twenty-six patients of breast cancer with pleural effusion have been treated with this therapy since 1983. PEL expanded and tumor cells collapsed by day 9 in culture with TCGF. Cultured PEL possessed significantly higher cytotoxic activity against autologous tumor cells than PBL cultured in the same condition (p less than 0.05), but there was no difference between their cytotoxic activities against K562. The proliferation rate of PEL obtained after intrapleural administration of OK-432 was higher than that obtained before OK-432 (p less than 0.01). Moreover, the cytotoxic activities against both autologous tumor and K562 of cultured PEL obtained after OK-432 administration was significantly (p less than 0.05) higher than those cultured PEL obtained before. Cultured PEL (1 x 10(8)-6 x 10(9)) were transferred into the pleural cavity after the intrapleural administration of OK-432 (1-5 KE). The volume of pleural effusion increased temporarily after the administration of OK-432 but significantly (p less than 0.01) decreased after AIT. Tumor cells disappeared cytologically in 22 patients at the last puncture of pleural effusion. Pleural effusion disappeared completely in 19 of 26 patients and decreased by more than 50% in volume in 6 patients. Performance status improved in 22 patients. The response rate for OK-432-combined AIT in the present study was 96%. The survival period of the patients treated by OK-432-combined AIT in this trial was significantly (p less than 0.002) prolonged compared to that of the patients receiving chemotherapy alone.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: 1st Department of Surgery, School of Medicine, Kyoto University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hori
authors.forename: K
authors.initials: K
authors.lastname: Mise
authors.forename: N
authors.initials: N
authors.lastname: Kan
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: K
authors.initials: K
authors.lastname: Satoh
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Teramura
authors.forename: T
authors.initials: T
authors.lastname: Harada
authors.forename: K
authors.initials: K
authors.lastname: Ohgaki
authors.forename: H
authors.initials: H
authors.lastname: Kodama
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000150:complications / Q000628:therapy*; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D010994:Pleura; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000473:pathology* / Q000628:therapy
chemical_list: D007376:Interleukin-2; D010844:Picibanil